Dermatology - European Medical Journal

This site is intended for healthcare professionals

Continue

Dermatology

Filter
29 Jul 2026

Delgocitinib Cream Showed Dose Dependent Benefits in Atopic Dermatitis

An 8 week Phase IIb trial found that delgocitinib cream produced dose dependent improvements in adults with mild to severe atopic dermatitis while maintaining a favourable safety profile compared with cream vehicle.
27 Jul 2026

Stevens Johnson Syndrome Risk Highest with Lamotrigine

A nationwide cohort quantified Stevens Johnson syndrome and toxic epidermal necrolysis risk after antiseizure medication initiation.
Photosensitive Disease Scoring Improved with UV Weighting - EMJ
24 Jul 2026

UV-Weighted Scoring Improves Photosensitive Disease Assessment

Researchers have developed a UV-weighted scoring system that could improve the assessment of photosensitive skin diseases by reducing body surface area-related bias.
22 Jul 2026

High-Dose Vitamin D Eases Cancer Therapy Skin Toxicity

High-dose oral vitamin D was associated with rapid improvement in chemotherapy- and radiation-induced skin toxicity in a multicentre case series of 33 patients.
20 Jul 2026

Rituximab Supports First-Line Treatment in Pemphigus Foliaceus

A meta-analysis found rituximab achieved complete remission in 75% of patients with pemphigus foliaceus, supporting its use as first-line treatment.
Sertaconazole Nanoemulsion Gel for Fungal Infections - EMJ
17 Jul 2026

Novel Formulation Targets Deep Fungal Skin Infections

A novel sertaconazole nanoemulsion gel improved skin penetration and antifungal efficacy compared with a commercial cream in preclinical testing.
New Sensor Tracks Skin Hydration Atopic Dermatitis - EMJ
17 Jul 2026

Skin Hydration Sensor for Monitoring Atopic Dermatitis at Home

A compact infrared device measures skin hydration in atopic dermatitis, opening the door to objective, home-based eczema monitoring.
Icotrokinra Psoriasis Trial Shows Durable Response - EMJ
10 Jul 2026

Icotrokinra Maintains Psoriasis Skin Clearance Through 52 Weeks

One-year Phase III data show icotrokinra delivered durable skin clearance and symptom improvement in adults with moderate-to-severe plaque psoriasis.
We’ve noticed you’re accessing
from North/South America.